drugset / Trial / NCT04507269
Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China
Phase 2
Completed
21 enrolled
Brii Biosciences Limited
Alnylam Pharmaceuticals · collabVir Biotechnology, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is to evaluate the safety, pharmacokinetics characteristics, and antiviral activities of multiple doses of VIR-2218 in adults with chronic HBV infection in mainland China.
Timeline
- Start
- 2020-08-18
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VIR-2218 | Small interfering RNA (siRNA) | — | Subcutaneous |